The development of direct-acting antivirals against hepatitis C virus (HCV) has transformed the treatment landscape and underpinned the WHO goal of HCV elimination by 2030. However, as of 2021, few countries remain on track to achieve this goal. Reliable data remain scarce, especially those on national plans for HCV elimination in many regions of the world and particularly in sub-Saharan Africa, which accounts for around 11 million of 71 million people estimated to be living with HCV.
We surveyed the membership in the HCV sub-Saharan Africa Network, consisting of blood transfusion service experts and lead physicians for HCV treatment to gain an understanding of the size of the challenge that sub-Saharan Africa faces. The network was developed through funding from the Global Challenges Research Fund by the Scottish Funding Council. This collaboration resulted in the development of a network of 25 senior treating physicians across 13 countries, many of whom are head of their national viral hepatitis programs, and 13 blood transfusion service experts across 12 countries. The full article can be accessed here.